Press Release Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer Submission based on results from the TROPION-Breast01 phase 3 trial Tokyo - (March 14, 2024) - Daiichi Sankyo (TSE: 4568) has submitted a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on 14 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2024 06:12:11 UTC.